Thursday, July 11, 2024 7:55:43 PM
learningvurve2020,
Yes they have developed automated manufacturing and the linchpin for L is Flaskworks which is wholly owned by NWBO. The concept of DCVax being a platform technology has been touted by Linda for many years too and has been found in most opening headers that introduce DCVax to any group at conferences. I guess you weren’t paying attention or don’t realize that DCs will do the same work they are designed to do in every antigen identification and presentation situation they are in as long as proper activation and signaling allows them to do that. This is especially important in the tumor microenvironment or anywhere other diseases are involved and that includes about 85% of all disease states that DCs can be involved in. If you would read a little about the science of DCs you would not put yourself in such a bad position by pretending DCs are not involved in that much disease activity in the human body or by not realizing that proteomics points to identification of viral and bacterial vectors identified as potentially involved in cancer disease state as well.
While you worry about one or two CDMOs maybe you might want to consider that it would take about 1,000 Advents to treat every new cancer patient in the world each year let alone those with ongoing states of cancer. Maybe try to wrap your head around who might be able to help ramp up with that, the transition to Direct that eliminates the need for surgery and then other disease states. Please don’t think too long though because otherwise someone will put up another exploding head emoji; ). Best wishes.
Yes they have developed automated manufacturing and the linchpin for L is Flaskworks which is wholly owned by NWBO. The concept of DCVax being a platform technology has been touted by Linda for many years too and has been found in most opening headers that introduce DCVax to any group at conferences. I guess you weren’t paying attention or don’t realize that DCs will do the same work they are designed to do in every antigen identification and presentation situation they are in as long as proper activation and signaling allows them to do that. This is especially important in the tumor microenvironment or anywhere other diseases are involved and that includes about 85% of all disease states that DCs can be involved in. If you would read a little about the science of DCs you would not put yourself in such a bad position by pretending DCs are not involved in that much disease activity in the human body or by not realizing that proteomics points to identification of viral and bacterial vectors identified as potentially involved in cancer disease state as well.
While you worry about one or two CDMOs maybe you might want to consider that it would take about 1,000 Advents to treat every new cancer patient in the world each year let alone those with ongoing states of cancer. Maybe try to wrap your head around who might be able to help ramp up with that, the transition to Direct that eliminates the need for surgery and then other disease states. Please don’t think too long though because otherwise someone will put up another exploding head emoji; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
